US Pharma MarketingStrain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: BioPharma Dive